Sugammadex Synthesis via Halogenated Cyclodextrin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for synthesizing Sugammadex face challenges such as the difficulty in removing triphenylphosphine oxide by-products, the use of hazardous and toxic reagents like NaH and DMF, and low yields, which complicate the production and purification of the pharmaceutical product.
Innovation Solution
A novel synthetic route involving the substitution of primary hydroxyl groups of γ-cyclodextrin with halogens, followed by reaction with 3-mercaptopropionic acid in the presence of a sodium base and DMSO, which enhances yield and avoids the use of toxic solvents like DMF, achieving high purity and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the conventional process using PPh3/I2 and DMF is used for synthesizing Sugammadex, then the reaction can proceed, but the yield is low (43%) and toxic by-products are formed that are difficult to remove
Solution Approach 1:
The patent changes the chemical parameters by replacing the reagent system from PPh3/I2/DMF to PX3/PX5/DMF, where X = F, Cl, Br, I. This parameter change results in better yield and purity while avoiding the formation of difficult-to-remove triphenylphosphine oxide by-products
Solution Approach 2:
The patent uses PX3 or PX5 reagents that can be easily removed or decomposed after the reaction, unlike the persistent triphenylphosphine oxide by-product. These reagents serve their purpose and can be disposed of more easily, improving both yield and purification
2Ease of manufacture
If NaH is used as the base in the second step, then the reaction can proceed, but NaH is hazardous and difficult to handle
Solution Approach 1:
The patent replaces hazardous NaH with safer alternatives like K2CO3, Cs2CO3, or KI that are less hazardous and easier to handle on large scale. These reagents achieve the same chemical function without the safety concerns of NaH
Solution Approach 2:
The patent changes the base parameter from strong base (NaH) to milder bases (K2CO3, Cs2CO3, KI), which reduces hazard while maintaining reaction effectiveness. This parameter change improves safety and ease of handling
3Object-affected harmful factors
If DMF is used as solvent, then the reaction can proceed, but DMF is toxic and difficult to work with on large scale
Solution Approach 1:
The patent changes the solvent parameter from DMF to DMSO, which has similar or better solvating properties but is less toxic and safer to handle on large scale. This parameter change reduces toxicity while maintaining or improving reaction efficiency
4Manufacturing precision
If PX5 or PX3 are used instead of PPh3/I2, then the yield and purity are improved, but these compounds are toxic and corrosive producing fumes
Solution Approach 1:
The patent uses PX3 or PX5 reagents that, while more hazardous during handling, can be easily removed or decomposed after the reaction. The key advantage is that they don't form persistent by-products like triphenylphosphine oxide, and the excess reagent can be destroyed by adding water or alcohol, converting it to harmless PX and HX
Solution Approach 2:
The patent acknowledges the hazard of PX3/PX5 but converts this harm into benefit by providing simple quenching procedures (adding water or alcohol) that destroy the hazardous reagent and convert it to harmless products, while the main benefit is avoiding persistent by-products and improving yield
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process achieves a yield of above 95% Sugammadex with improved purity, minimizing impurities and reducing the handling difficulties associated with hazardous reagents, while using safer solvents like DMSO, thus providing an efficient and safer method for large-scale production.
Implementation Method 1
Substituting the primary hydroxyl groups of the γ-cyclodextrin by halogen to give the corresponding 6-per-deoxy-6-per-halo-γ-cyclodextrin compound
Implementation Method 2
Reacting the compound of formula (3) with 3-mercaptopropionic acid in the presence of a sodium base and DMSO
Implementation Method 3
Reacting the compound of formula (3) with 3-mercaptopropionic acid in the presence of a sodium base and DMSO
Data Source
AI summary
The invention relates to a novel process for making the pharmaceutical product Sugammadex. OVERVIEW OF THE PRIOR ART Sugammadex, i.e. 5-Cyclooctakis-(1→4)- [6-S-(2-carboxyethyl)-6-thio-alfa-D-glucopyranosyl] of formula (I), is a modified γ-cyclodextrin. Sugammadex is the first selective relaxant binding agent for reversal of neuromuscular blockade by the agent rocuronium or vecuronium in general anesthesia. It was approved in 2008